Cargando…

Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi

BACKGROUND: The most common apicomplexan parasites causing bovine babesiosis are Babesia bovis and B. bigemina, while B. caballi and Theileria equi are responsible for equine piroplasmosis. Treatment and control of these diseases are usually achieved using potentially toxic chemotherapeutics, such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Marta G., Bastos, Reginaldo G., Stone Doggett, J., Riscoe, Michael K., Pou, Sovitj, Winter, Rolf, Dodean, Rozalia A., Nilsen, Aaron, Suarez, Carlos E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712603/
https://www.ncbi.nlm.nih.gov/pubmed/33272316
http://dx.doi.org/10.1186/s13071-020-04487-3
_version_ 1783618408398454784
author Silva, Marta G.
Bastos, Reginaldo G.
Stone Doggett, J.
Riscoe, Michael K.
Pou, Sovitj
Winter, Rolf
Dodean, Rozalia A.
Nilsen, Aaron
Suarez, Carlos E.
author_facet Silva, Marta G.
Bastos, Reginaldo G.
Stone Doggett, J.
Riscoe, Michael K.
Pou, Sovitj
Winter, Rolf
Dodean, Rozalia A.
Nilsen, Aaron
Suarez, Carlos E.
author_sort Silva, Marta G.
collection PubMed
description BACKGROUND: The most common apicomplexan parasites causing bovine babesiosis are Babesia bovis and B. bigemina, while B. caballi and Theileria equi are responsible for equine piroplasmosis. Treatment and control of these diseases are usually achieved using potentially toxic chemotherapeutics, such as imidocarb diproprionate, but drug-resistant parasites are emerging, and alternative effective and safer drugs are needed. The endochin-like quinolones (ELQ)-300 and ELQ-316 have been proven to be safe and efficacious against related apicomplexans, such as Plasmodium spp., with ELQ-316 also being effective against Babesia microti, without showing toxicity in mammals. METHODS: The inhibitory effects of ELQ-300 and ELQ-316 were assessed on the growth of cultured B. bovis, B. bigemina, B. caballi and T. equi. The percentage of parasitized erythrocytes was measured by flow cytometry, and the effect of the ELQ compounds on the viability of horse and bovine peripheral blood mononuclear cells (PBMC) was assessed by monitoring cell metabolic activity using a colorimetric assay. RESULTS: We calculated the half maximal inhibitory concentration (IC(50)) at 72 h, which ranged from 0.04 to 0.37 nM for ELQ-300, and from 0.002 to 0.1 nM for ELQ-316 among all cultured parasites tested at 72 h. None of the parasites tested were able to replicate in cultures in the presence of ELQ-300 and ELQ-316 at the maximal inhibitory concentration (IC(100)), which ranged from 1.3 to 5.7 nM for ELQ-300 and from 1.0 to 6.0 nM for ELQ-316 at 72 h. Neither ELQ-300 nor ELQ-316 altered the viability of equine and bovine PBMC at their IC(100) in in vitro testing. CONCLUSIONS: The compounds ELQ-300 and ELQ-316 showed significant inhibitory activity on the main parasites responsible for bovine babesiosis and equine piroplasmosis at doses that are tolerable to host cells. These ELQ drugs may be viable candidates for developing alternative protocols for the treatment of bovine babesiosis and equine piroplasmosis. [Image: see text]
format Online
Article
Text
id pubmed-7712603
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77126032020-12-03 Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi Silva, Marta G. Bastos, Reginaldo G. Stone Doggett, J. Riscoe, Michael K. Pou, Sovitj Winter, Rolf Dodean, Rozalia A. Nilsen, Aaron Suarez, Carlos E. Parasit Vectors Research BACKGROUND: The most common apicomplexan parasites causing bovine babesiosis are Babesia bovis and B. bigemina, while B. caballi and Theileria equi are responsible for equine piroplasmosis. Treatment and control of these diseases are usually achieved using potentially toxic chemotherapeutics, such as imidocarb diproprionate, but drug-resistant parasites are emerging, and alternative effective and safer drugs are needed. The endochin-like quinolones (ELQ)-300 and ELQ-316 have been proven to be safe and efficacious against related apicomplexans, such as Plasmodium spp., with ELQ-316 also being effective against Babesia microti, without showing toxicity in mammals. METHODS: The inhibitory effects of ELQ-300 and ELQ-316 were assessed on the growth of cultured B. bovis, B. bigemina, B. caballi and T. equi. The percentage of parasitized erythrocytes was measured by flow cytometry, and the effect of the ELQ compounds on the viability of horse and bovine peripheral blood mononuclear cells (PBMC) was assessed by monitoring cell metabolic activity using a colorimetric assay. RESULTS: We calculated the half maximal inhibitory concentration (IC(50)) at 72 h, which ranged from 0.04 to 0.37 nM for ELQ-300, and from 0.002 to 0.1 nM for ELQ-316 among all cultured parasites tested at 72 h. None of the parasites tested were able to replicate in cultures in the presence of ELQ-300 and ELQ-316 at the maximal inhibitory concentration (IC(100)), which ranged from 1.3 to 5.7 nM for ELQ-300 and from 1.0 to 6.0 nM for ELQ-316 at 72 h. Neither ELQ-300 nor ELQ-316 altered the viability of equine and bovine PBMC at their IC(100) in in vitro testing. CONCLUSIONS: The compounds ELQ-300 and ELQ-316 showed significant inhibitory activity on the main parasites responsible for bovine babesiosis and equine piroplasmosis at doses that are tolerable to host cells. These ELQ drugs may be viable candidates for developing alternative protocols for the treatment of bovine babesiosis and equine piroplasmosis. [Image: see text] BioMed Central 2020-12-03 /pmc/articles/PMC7712603/ /pubmed/33272316 http://dx.doi.org/10.1186/s13071-020-04487-3 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Silva, Marta G.
Bastos, Reginaldo G.
Stone Doggett, J.
Riscoe, Michael K.
Pou, Sovitj
Winter, Rolf
Dodean, Rozalia A.
Nilsen, Aaron
Suarez, Carlos E.
Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi
title Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi
title_full Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi
title_fullStr Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi
title_full_unstemmed Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi
title_short Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi
title_sort endochin-like quinolone-300 and elq-316 inhibit babesia bovis, b. bigemina, b. caballi and theileria equi
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712603/
https://www.ncbi.nlm.nih.gov/pubmed/33272316
http://dx.doi.org/10.1186/s13071-020-04487-3
work_keys_str_mv AT silvamartag endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi
AT bastosreginaldog endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi
AT stonedoggettj endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi
AT riscoemichaelk endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi
AT pousovitj endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi
AT winterrolf endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi
AT dodeanrozaliaa endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi
AT nilsenaaron endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi
AT suarezcarlose endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi